Poly(polyol sebacate) Elastomers as Coatings for Metallic Coronary Stents

Electrospraying: Possibilities and Challenges of Engineering Carriers for Biomedical Applications-A Mini Review

Electrospraying, a liquid atomization-based technique, has been used to produce and formulate micro/nanoparticular cargo carriers for various biomedical applications, including drug delivery, biomedical imaging, implant coatings, and tissue engineering. In this mini review, we begin with the main features of electrospraying methods to engineer carriers with various bioactive cargos, including genes, growth factors, and enzymes. In particular, this review focuses on the improvement of traditional electrospraying technology for the fabrication of carriers for living cells and providing a suitable condition for gene transformation. Subsequently, the major applications of the electrosprayed carriers in the biomedical field are highlighted. Finally, we finish with conclusions and future perspectives of electrospraying for high efficiency and safe production.

In vitro and in vivo evaluation of a dextran-graft-polybutylmethacrylate copolymer coated on CoCr metallic stent

Introduction: The major complications of stent implantation are restenosis and late stent thrombosis. PBMA polymers are used for stent coating because of their mechanical properties. We previously synthesized and characterized Dextrangraft-polybutylmethacrylate copolymer (Dex-PBMA) as a potential stent coating. In this study, we evaluated the haemocompatibility and biocompatibility properties of Dex-PBMA in vitro and in vivo. Methods: Here, we investigated: (1) the effectiveness of polymer coating under physiological conditions and its ability to release Tacrolimus®, (2) the capacity of Dex-PBMA to inhibit Staphylococcus aureus adhesion, (3) the thrombin generation and the human platelet adhesion in static and dynamic conditions, (4) the biocompatibility properties in vitro on human endothelial colony forming cells ( ECFC) and on mesenchymal stem cells (MSC) and in vivo in rat models, and (5) we implanted Dex-PBMA and Dex-PBMA_TAC coated stents in neointimal hyperplasia restenosis rabbit model. Results: Dex-PBMA coating efficiently prevented bacterial adhesion and release Tacrolimus®. Dex-PBMA exhibit haemocompatibility properties under flow and ECFC and MSC compatibility. In vivo, no pathological foreign body reaction was observed neither after intramuscular nor intravascular aortic implantation. After Dex-PBMA and Dex-PBMA_TAC coated stents 30 days implantation in a restenosis rabbit model, an endothelial cell coverage was observed and the lumen patency was preserved. Conclusion: Based on our findings, Dex-PBMA exhibited vascular compatibility and can potentially be used as a coating for metallic coronary stents.